Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol

BACKGROUND: Clinical practice guidelines recommend dual long-acting muscarinic antagonists (LAMAs)/long-acting β(2)agonists (LABAs) as maintenance therapy in patients with chronic obstructive pulmonary disease (COPD) and dyspnea or exercise intolerance. Escalation to triple therapy (TT) (LAMA/LABA/i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Sanjay, Palli, Swetha R, Bengtson, Lindsay G S, Buysman, Erin K, Clark, Brendan, Sargent, Andrew, Shaikh, Asif, Ferguson, Gary T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394184/
https://www.ncbi.nlm.nih.gov/pubmed/37133429
http://dx.doi.org/10.18553/jmcp.2023.22373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394184/
https://www.ncbi.nlm.nih.gov/pubmed/37133429
http://dx.doi.org/10.18553/jmcp.2023.22373

Ejemplares similares